Cargando…
Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells
BACKGROUND: Calciprotein particles (CPPs), colloidal mineral-protein nanoparticles, have emerged as potential mediators of phosphate toxicity in dialysis patients, with putative links to vascular calcification, endothelial dysfunction and inflammation. We hypothesized that phosphate binder therapy w...
Autores principales: | Thiem, Ursula, Hewitson, Tim D, Toussaint, Nigel D, Holt, Stephen G, Haller, Maria C, Pasch, Andreas, Cejka, Daniel, Smith, Edward R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157755/ https://www.ncbi.nlm.nih.gov/pubmed/36107466 http://dx.doi.org/10.1093/ndt/gfac271 |
Ejemplares similares
-
The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial
por: Thiem, Ursula, et al.
Publicado: (2020) -
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
por: Floege, Jürgen, et al.
Publicado: (2015) -
One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis
por: Kendrick, Jessica, et al.
Publicado: (2019) -
Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial
por: Smith, Edward R., et al.
Publicado: (2020) -
Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide
por: Covic, Adrian C., et al.
Publicado: (2017)